Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
About this item
Full title
Author / Creator
Publisher
Germany: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Germany: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
While localized prostate cancer (PCa) can be effectively cured, metastatic disease inevitably progresses to a lethal state called castration-resistant prostate cancer (CRPC). Emerging evidence suggests that aberrant epigenetic repression by the polycomb group (PcG) complexes fuels PCa progression, providing novel therapeutic opportunities.
In th...
Alternative Titles
Full title
Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4751702
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4751702
Other Identifiers
ISSN
1868-7075,1868-7083
E-ISSN
1868-7083,1868-7075
DOI
10.1186/s13148-016-0182-9
